Maintenance of endoscopic remission in UC (RR > 1 favors FMT) · Patients with quiescent ulcerative colitis
It is very uncertain whether fecal microbiota transplantation changes maintenance of endoscopic remission in UC (RR > 1 favors FMT) compared with control (very low certainty).
1 finding from 1 review
Surgical intervention (e.g. endoscopic balloon dilation, cricoid split, tracheostomy) for stridor or subglottic stenosis Time of measurement: during initial hospitalization · neonates
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
1 finding from 1 review
Endoscopic recurrence · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
Intensification of prophylactic therapy guided by colonoscopy may leads to lower endoscopic recurrence ( compared with intensification guided by clinical recurrence (low certainty).
1 finding from 1 review
Endoscopic recurrence · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
It is very uncertain whether initiation of prophylactic therapy guided by colonoscopy changes endoscopic recurrence (at week 102) compared with initiation of prophylactic therapy immediately after surgery (very low certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve endoscopic remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain endoscopic remission · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain clinical or endoscopic response with prior TNF‐α… compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · People with quiescent Crohn's disease (ileocolic resection)
It is very uncertain whether adalimumab changes failure to maintain endoscopic remission compared with active comparator (very low certainty).
1 finding from 1 review